A new study has highlighted a potential way to protect memory in the early stages of Alzheimer-related disease, offering cautious optimism for families worried about cognitive decline. The work explores how a common cellular molecule called NAD may help stabilise brain function by correcting disruptions in the way nerve cells process genetic messages. The findings were published in ScienceAdvances.
Researchers examined how NAD levels influence alternative RNA splicing, a process that allows cells to create different forms of the same protein. This mechanism is essential for healthy brain activity and becomes increasingly unstable in Alzheimer related conditions. According to the findings in the uploaded study, errors in RNA splicing were widespread in mouse models of tau driven disease and appeared to intensify with age. The researchers also observed similar abnormalities in a roundworm model, where faulty splicing was linked with early memory impairment.
The team focused particularly on a protein called EVA1C, which is involved in the development and stability of nerve connections. The study found that Alzheimer related models showed marked changes to the way EVA1C is produced. When NAD levels were increased using the precursor compounds NR and NMN, the splicing of EVA1C shifted toward healthier patterns and the animals demonstrated clearer improvements in memory linked behaviour. In mouse tests using the novel object recognition task, animals with tau pathology performed poorly at recognising new objects, but those given NMN regained performance similar to healthy controls. These benefits disappeared when EVA1C was deliberately reduced, suggesting it plays a central role in the protective effect.
The findings suggest that NAD may support neural resilience by restoring the correct balance of EVA1C forms and strengthening the activity of chaperone proteins such as HSP70, which help maintain cell stability. The study’s modelling work indicates that specific EVA1C variants interact more effectively with HSP70 during NAD supplementation, potentially reducing the build up of harmful tau species in the brain. This mechanistic insight offers researchers a clearer picture of how cellular metabolism might influence the course of dementia.
Human data referenced in the study also point toward clinical relevance. Brain tissue from people with Alzheimer related disease showed reduced levels of EVA1C in key regions such as the hippocampus and entorhinal cortex, areas strongly linked with early memory loss. These tissue findings were supported by multiple public datasets, which indicated that EVA1C expression patterns correlate with the severity of tau and amyloid pathology. Although the human evidence is observational, the consistency across datasets strengthens the case that EVA1C and NAD related pathways may play a meaningful part in disease progression.
Scientists emphasise that NAD boosting supplements are not proven Alzheimer treatments. However, the cross species data summarised in the study suggest that restoring NAD levels could address an overlooked aspect of disease biology linked with RNA splicing and neuronal integrity. The authors propose that future therapies may combine NAD augmentation with approaches that target splicing directly, offering a new angle for research into cognitive decline.
